BCI
CAPR icon

Brinker Capital Investments’s Capricor Therapeutics CAPR Stock Holding History

Brinker Capital Investments’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$235K Sell
9,746
-375
-4% -$11.4K ﹤0.01% 1742
2026
Q1 		$308K Buy
10,121
+1,855
+22% +$49.4K ﹤0.01% 1660
2025
Q4 		$239K Buy
+8,266
New +$108K ﹤0.01% 1927

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Brinker Capital Investments's CAPR Position: Q2 2026 in Review

Brinker Capital Investments reduced its Capricor Therapeutics (CAPR) stake by 3.7% in Q2 2026, selling an estimated $11.4K and leaving 9,746 shares worth $235K. The position accounts for ﹤0.01% of the portfolio, ranked #1742.

Brinker Capital Investments first reported a position in CAPR in Q4 2025 and has held it in 3 quarters since. The position peaked at $308K in Q1 2026. 169 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • Brinker Capital Investments held 9,746 shares of Capricor Therapeutics worth $235K as of Q2 2026.
  • Brinker Capital Investments sold 375 Capricor Therapeutics shares in Q2 2026, an estimated $11.4K.
  • Capricor Therapeutics made up ﹤0.01% of Brinker Capital Investments's portfolio in Q2 2026, its #1742 holding.
  • Brinker Capital Investments first reported a position in Capricor Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Brinker Capital Investments's Capricor Therapeutics position peaked at $308K in Q1 2026.
  • 169 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Brinker Capital Investments's 13F filing for Q2 2026, filed 14 Aug 2026.